Multivariate logistic regression to identify factors predictive of achieving SVR among per-protocol patients treated for 24 weeks.

<p>Multivariate logistic regression to identify factors predictive of achieving SVR among per-protocol patients treated for 24 weeks.</p

Impact of BMI on baseline histopathology and HOMA-IR.

<p>Box plots displaying the 10^th, 25^th, 50^th, 75^th, and 90^th percentiles of BMI among patients grouped by steatosis grade (A; n = 279) and fibrosis stage (B; n = 279), as well as HOMA-IR among patients grouped according to BMI (C; n = 268). P-values obtained using Kruskal-Wallis test.</p

Impact of obesity on ribavirin concentrations.

<p>Box plots displaying the 10^th, 25^th, 50^th, 75^th, and 90^th percentiles of the plasma concentrations of ribavirin (µg/mL) treatment day 29 and week 12 (<b>A</b> and <b>B</b> respectively). P-values obtained using Mann-Whitney U-test.</p

Baseline Characteristics of the Patients Grouped by BMI (Per-Protocol Analysis).

a<p>No. (%);</p>b<p>Mean (SD);</p>c<p>Median (Range);</p>d<p>Chi square test,</p>e<p>Mann-Whitney U-test; two patients were infected with both genotype 2 and 3.</p

Impact of obesity on interferon concentrations.

<p>Box plots displaying the 10^th, 25^th, 50^th, 75^th, and 90^th percentiles of the plasma concentrations of peginterferon (pg/mL) treatment day 3, 7, and 29 (<b>A–C</b> respectively). P-values obtained using Mann-Whitney U-test.</p

Impact of obesity on outcome.

<p>Histogram displaying the proportion achieving cEVR, SVR, relapse or non-response among patients treated for 24 weeks included in the per-protocol analysis grouped according to BMI. P-value obtained using Chi-squared test.</p

Impact of interferon concentration on first phase decline in HCV RNA.

<p>Correlation between the plasma concentration of peginterferon (pg/mL) treatment day 3 and decline in HCV RNA (log₁₀ IU/mL) between baseline and treatment day 3 of combination therapy evaluated by use of Spearman's rank correlation coefficient <i>r_s</i> test.</p

Frequency distribution of <i>IL28B</i> variants in relation to HCV genotypes 1-3.

<p>Frequency distribution of <i>IL28B</i> variants in relation to HCV genotypes 1-3.</p

Tenth, 25^th, 50^th, 75^th, and 90^th percentiles of pretreatment IP-10 in relation to <i>IL28B</i> variants.

<p>Tenth, 25^th, 50^th, 75^th, and 90^th percentiles of pretreatment IP-10 in relation to <i>IL28B</i> variants.</p

The impact of <i>IL28B</i> genetic variations and baseline plasma IP-10 on the likelihood of achieving RVR among patients infected with HCV genotype 1.

<p>All P-values using Chi squared test.</p>a<p>P-values for SNP genotypes and frequency of RVR irrespective of baseline IP-10.</p